Icad Inc ICAD
We take great care to ensure that the data presented and summarized in this overview for ICAD INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ICAD
View all-
Vanguard Group Inc Valley Forge, PA1.13MShares$1.96 Million0.0% of portfolio
-
First Eagle Investment Management, LLC675KShares$1.17 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny601KShares$1.04 Million0.0% of portfolio
-
Black Rock Inc. New York, NY350KShares$605,4530.0% of portfolio
-
Amh Equity LTD296KShares$512,1690.64% of portfolio
-
Greenwood Capital Associates LLC Greenwood, SC295KShares$510,6040.06% of portfolio
-
Geode Capital Management, LLC Boston, MA259KShares$448,8200.0% of portfolio
-
Act Capital Management, LLC Wayne, PA205KShares$354,6500.59% of portfolio
-
General American Investors CO Inc200KShares$346,7500.02% of portfolio
-
Perritt Capital Management Inc Chicago, IL186KShares$320,9150.16% of portfolio
Latest Institutional Activity in ICAD
Top Purchases
Top Sells
About ICAD
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Insider Transactions at ICAD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 31
2023
|
Dana R Brown Director |
BUY
Open market or private purchase
|
Direct |
40,000
+50.0%
|
$40,000
$1.3 P/Share
|
Sep 12
2022
|
Jonathan Go Officer |
SELL
Open market or private sale
|
Direct |
38,960
-8.6%
|
$77,920
$2.7 P/Share
|
Sep 12
2022
|
Jonathan Go Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+16.5%
|
$90,000
$2.27 P/Share
|
Mar 03
2022
|
Timothy Norris Irish Director |
BUY
Open market or private purchase
|
Direct |
5,500
+50.0%
|
$22,000
$4.63 P/Share
|
Feb 08
2022
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.83%
|
$50,000
$5.49 P/Share
|
Feb 07
2022
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.82%
|
$50,000
$5.26 P/Share
|
Jan 31
2022
|
Jonathan Go Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.87%
|
$40,000
$2.9 P/Share
|
Jan 07
2022
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.81%
|
$60,000
$6.07 P/Share
|
Jan 06
2022
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.81%
|
$60,000
$6.2 P/Share
|
Jan 05
2022
|
Stacey M Stevens CEO and President |
BUY
Open market or private purchase
|
Direct |
17,006
+9.91%
|
$102,036
$6.17 P/Share
|
Dec 09
2021
|
Nathaniel Dalton Director |
BUY
Open market or private purchase
|
Indirect |
6,900
+3.62%
|
$48,300
$7.24 P/Share
|
Dec 08
2021
|
Charles Ross Carter CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$49,000
$7.05 P/Share
|
Dec 08
2021
|
Michael S Klein Director |
BUY
Open market or private purchase
|
Direct |
13,475
+25.29%
|
$94,325
$7.38 P/Share
|
Dec 08
2021
|
Susan Alyson Wood Director |
BUY
Open market or private purchase
|
Direct |
1,500
+26.62%
|
$10,500
$7.31 P/Share
|
Dec 07
2021
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.8%
|
$70,000
$7.28 P/Share
|
Dec 06
2021
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.79%
|
$60,000
$6.71 P/Share
|
Nov 09
2021
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.79%
|
$100,000
$10.3 P/Share
|
Nov 08
2021
|
Andy Sassine Director |
SELL
Open market or private sale
|
Direct |
10,000
-0.78%
|
$100,000
$10.89 P/Share
|
Nov 08
2021
|
Jonathan Go Officer |
SELL
Open market or private sale
|
Direct |
8,750
-5.78%
|
$87,500
$10.86 P/Share
|
Nov 08
2021
|
Jonathan Go Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+16.53%
|
$90,000
$3.15 P/Share
|